Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Chemother Pharmacol ; 75(5): 897-906, 2015 May.
Article in English | MEDLINE | ID: mdl-25724157

ABSTRACT

Clofarabine, a deoxyadenosine analog, was an active anticancer drug in our in vitro high-throughput screening against mouse ependymoma neurospheres. To characterize the clofarabine disposition in mice for further preclinical efficacy studies, we evaluated the plasma and central nervous system disposition in a mouse model of ependymoma. A plasma pharmacokinetic study of clofarabine (45 mg/kg, IP) was performed in CD1 nude mice bearing ependymoma to obtain initial plasma pharmacokinetic parameters. These estimates were used to derive D-optimal plasma sampling time points for cerebral microdialysis studies. A simulation of clofarabine pharmacokinetics in mice and pediatric patients suggested that a dosage of 30 mg/kg IP in mice would give exposures comparable to that in children at a dosage of 148 mg/m(2). Cerebral microdialysis was performed to study the tumor extracellular fluid (ECF) disposition of clofarabine (30 mg/kg, IP) in the ependymoma cortical allografts. Plasma and tumor ECF concentration-time data were analyzed using a nonlinear mixed effects modeling approach. The median unbound fraction of clofarabine in mouse plasma was 0.79. The unbound tumor to plasma partition coefficient (K pt,uu: ratio of tumor to plasma AUCu,0-inf) of clofarabine was 0.12 ± 0.05. The model-predicted mean tumor ECF clofarabine concentrations were below the in vitro 1-h IC50 (407 ng/mL) for ependymoma neurospheres. Thus, our results show the clofarabine exposure reached in the tumor ECF was below that associated with an antitumor effect in our in vitro washout study. Therefore, clofarabine was de-prioritized as an agent to treat ependymoma, and further preclinical studies were not pursued.


Subject(s)
Adenine Nucleotides/pharmacology , Adenine Nucleotides/pharmacokinetics , Arabinonucleosides/pharmacology , Arabinonucleosides/pharmacokinetics , Brain Neoplasms/drug therapy , Brain Neoplasms/metabolism , Ependymoma/drug therapy , Ependymoma/metabolism , Adenine Nucleotides/blood , Adolescent , Animals , Antimetabolites, Antineoplastic/blood , Antimetabolites, Antineoplastic/pharmacokinetics , Antimetabolites, Antineoplastic/pharmacology , Arabinonucleosides/blood , Blood Proteins/metabolism , Brain/metabolism , Brain Neoplasms/blood , Child , Child, Preschool , Clofarabine , Ependymoma/blood , Female , Humans , Mice , Mice, Nude , Models, Biological , Tumor Cells, Cultured , Xenograft Model Antitumor Assays
2.
Neurobiol Dis ; 59: 26-37, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23859799

ABSTRACT

The p38 mitogen-activated protein kinase (MAPK) isoforms are phosphorylated by a variety of stress stimuli in neurodegenerative disease and act as upstream activators of myriad pathogenic processes. Thus, p38 MAPK inhibitors are of growing interest as possible therapeutic interventions. Axonal dysfunction is an early component of most neurodegenerative disorders, including the most prevalent optic neuropathy, glaucoma. Sensitivity to intraocular pressure at an early stage disrupts anterograde transport along retinal ganglion cell (RGC) axons to projection targets in the brain with subsequent degeneration of the axons themselves; RGC body loss is much later. Here we show that elevated ocular pressure in rats increases p38 MAPK activation in retina, especially in RGC bodies. Topical eye-drop application of a potent and selective inhibitor of the p38 MAPK catalytic domain (Ro3206145) prevented both the degradation of anterograde transport to the brain and degeneration of axons in the optic nerve. Ro3206145 reduced in the retina phosphorylation of tau and heat-shock protein 27, both down-stream targets of p38 MAPK activation implicated in glaucoma, as well as expression of two inflammatory responses. We also observed increased p38 MAPK activation in mouse models. Thus, inhibition of p38 MAPK signaling in the retina may represent a therapeutic target for preventing early pathogenesis in optic neuropathies.


Subject(s)
Axons/pathology , Enzyme Inhibitors/therapeutic use , Gene Expression Regulation/drug effects , Retinal Degeneration/prevention & control , Signal Transduction , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors , p38 Mitogen-Activated Protein Kinases/metabolism , Activating Transcription Factor 2/metabolism , Animals , Chaperonin 60/metabolism , Disease Models, Animal , Dose-Response Relationship, Drug , Imidazoles/therapeutic use , In Vitro Techniques , Intraocular Pressure/physiology , Intraocular Pressure/radiation effects , Mice , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Ocular Hypertension/complications , Ocular Hypertension/drug therapy , Ocular Hypertension/etiology , Pyridines/pharmacology , Pyridines/therapeutic use , Rats , Retina/drug effects , Retina/metabolism , Retina/radiation effects , Retinal Degeneration/etiology , Retinal Degeneration/pathology , Retinal Ganglion Cells/drug effects , Retinal Ganglion Cells/pathology , Signal Transduction/drug effects , Time Factors
3.
Mamm Genome ; 16(9): 672-82, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16245024

ABSTRACT

The mutant allelic series of the mouse quaking gene consists of the spontaneous quaking(viable) (qk(v)) allele, which is homozygous viable with a dysmyelination phenotype, and four ENU-induced alleles (qk(kt 1), qk(k2), qk(kt3/4), and qk(l-1)), which are homozygous embryonic lethal. Here we report the isolation of qk(e5), the first ENU-induced viable allele of quaking. Unlike qk(v)/qk(v), qk(e5)/qk(e5) animals have early-onset seizures, severe ataxia, and a dramatically reduced lifespan. Ultrastructural analysis of qk(e5)/qk(e5) brains reveals severe dysmyelination when compared with both wild-type and qk(v)/qk(v) brains. In addition, Calbindin detection in young adult qk(e5)/qk(e5) mice reveals Purkinje cell axonal swellings indicative of neurodegeneration , which is not seen in young adult qk(v)/qk(v) mice. Although the molecular defect in the qk(e5) allele is not evident by sequencing, protein expression studies show that qk(e5)/qk(e5) postnatal oligodendrocytes lack the QKI-6 and QKI-7 isoforms and have reduced QKI-5 levels. The oligodendrocyte developmental markers PDGF alpha R, NG 2, O4, CNP, and MBP are also present in the qk(e5)/qk(e5) postnatal brain although CNP and MBP levels are considerably reduced. Because the qk(v) allele is a large deletion that affects the expression of three genes, the new neurologic qk(e5) allele is an important addition to this allelic series.


Subject(s)
Alleles , Central Nervous System/ultrastructure , Demyelinating Diseases/genetics , Phenotype , RNA-Binding Proteins/genetics , Animals , Blotting, Northern , Calbindins , Crosses, Genetic , DNA Primers , Demyelinating Diseases/pathology , Ethylnitrosourea , Immunohistochemistry , Mice , Mice, Quaking , Microscopy, Electron, Transmission , Mutagenesis , S100 Calcium Binding Protein G , Sequence Analysis, DNA
4.
Mov Disord ; 20(10): 1369-74, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16001410

ABSTRACT

The quakingviable (qkv) mutant mouse shows a recessive neurological phenotype that includes central nervous system (CNS) dysmyelination, seizures, and tremor associated with voluntary movement. The molecular defect of qkv has been previously reported to be a spontaneous approximately 1 megabase (Mb) deletion in the proximal region of mouse chromosome 17 that occurred in the DBA mouse strain more than four decades ago. The mutation has recently been shown to affect three genes in the region: Quaking (qk), Parkin-coregulated gene (Pacrg), and Parkin. Here we determine the exact deletion breakpoints and demonstrate that the mutation is not just comprised of a approximately 1.1 Mb deletion, but also harbors a small 163 bp duplication fragment between the deletion breakpoints. Although the distal deletion breakpoint is within the fifth intron of the mouse Parkin gene, the duplicated sequence is derived from the sixth Parkin intron and shows positive transcriptional activity on a reporter gene in vitro. This complexity provides insight into a well-studied neurological mutant and may have a role in affecting the phenotype observed.


Subject(s)
Chromosomes, Mammalian/genetics , Gene Duplication , Inteins/genetics , Point Mutation/genetics , Ubiquitin-Protein Ligases/genetics , Animals , DNA Fragmentation/genetics , DNA Primers/genetics , Demyelinating Diseases/genetics , Gene Expression Regulation/genetics , Genes, Reporter/genetics , Humans , Mice , Mice, Quaking , Microfilament Proteins , Molecular Chaperones , Phenotype , Proteins/genetics , Transcriptional Activation/genetics
5.
Am J Hum Genet ; 72(5): 1101-16, 2003 May.
Article in English | MEDLINE | ID: mdl-12649807

ABSTRACT

To investigate the potential involvement of genome architecture in nonrecurrent chromosome rearrangements, we analyzed the breakpoints of eight translocations and 18 unusual-sized deletions involving human proximal 17p. Surprisingly, we found that many deletion breakpoints occurred in low-copy repeats (LCRs); 13 were associated with novel large LCR17p structures, and 2 mapped within an LCR sequence (middle SMS-REP) within the Smith-Magenis syndrome (SMS) common deletion. Three translocation breakpoints involving 17p11 were found to be located within the centromeric alpha-satellite sequence D17Z1, three within a pericentromeric segment, and one at the distal SMS-REP. Remarkably, our analysis reveals that LCRs constitute >23% of the analyzed genome sequence in proximal 17p--an experimental observation two- to fourfold higher than predictions based on virtual analysis of the genome. Our data demonstrate that higher-order genomic architecture involving LCRs plays a significant role not only in recurrent chromosome rearrangements but also in translocations and unusual-sized deletions involving 17p.


Subject(s)
Chromosome Breakage/genetics , Chromosomes, Human, Pair 17/genetics , Genome , Sequence Deletion/genetics , Translocation, Genetic/genetics , Centromere/genetics , Humans , In Situ Hybridization, Fluorescence/methods , Physical Chromosome Mapping , Repetitive Sequences, Nucleic Acid
SELECTION OF CITATIONS
SEARCH DETAIL
...